NPC in in Specialty Pharmacy Times: Aiming for Value Over Volume in Cancer Drug Spending
In his latest column for Specialty Pharmacy Times, NPC President Dan Leonard takes a closer look at a presidential panel's report on "Promoting Value, Affordability, and Innovation in Cancer Drug Treatment." The report cites NPC research on proposals including outcomes-based contracting, value assessment frameworks, and incentives to use high-value medicines and minimize out-of-pocket costs.
When an expert panel, appointed by President Donald Trump, released a report on “Promoting Value, Affordability, and Innovation in Cancer Drug Treatment,” it noted, “Innovations in cancer therapy, particularly in the development of targeted drugs and immunotherapies, hold remarkable potential to transform treatment of the disease.” But breakthrough medicines can only work in the patients who have access to them.
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President Dan Leonard takes a closer look at the panel's report, which cites NPC research on proposals including outcomes-based contracting, value assessment frameworks, and incentives to use high-value medicines and minimize out-of-pocket costs.
Leonard explains how these proposals, as well as working with all health care stakeholders, can help ensure that patients have access to innovative, high-value and affordable cancer medicines.
>> Read the Full Column on the Specialty Pharmacy Times Website